TNFRSF17 and plasma cell myeloma: Up to date, there are six CAR-T therapies approved by drug agencies worldwide (Kymriah®, Yescarta®, Tecartus®, Breyanzi® and ARI-0001 for CAR-T against CD19+ B-cell lymphoproliferative diseases, and Abecma® and Carvykti® for CAR-T anti-BCMA in multiple myeloma).